Skip to main content
Clinical Trials/NCT06898307
NCT06898307RecruitingNot Applicable

Utility of Gene Test Analysis for Diagnosis, Prognosis and Treatment of Patients With Genetic Arrhythmic Heart Disease: the ARRHYTHMIC GENE-HEART

University Hospital of Ferrara1 site in 1 country200 target enrollmentStarted: November 1, 2017Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
200
Locations
1
Primary Endpoint
All-cause of death

Study Overview

Brief Summary

The goal of this observational study is to enroll all patients evaluated at the specialized Cardiogenetic Center within the Cardiology Department of the University of Ferrara, Italy. The primary aim of the registry is to collect comprehensive clinical, genetic, and electrophysiological data from individuals with suspected or confirmed arrhythmogenic conditions. By systematically documenting patient demographics, family history, clinical presentations, diagnostic findings, and treatment outcomes, the registry seeks to enhance our understanding of the genetic basis and clinical implications of genetically driven arrhythmias and systemic syndromes. This registry will facilitate long-term follow-up of enrolled patients to assess the natural history of arrhythmogenic disorders and the effectiveness of various therapeutic interventions. Additionally, it aims to identify potential risk factors associated with adverse outcomes, such as sudden cardiac death or major arrhythmic events.

Detailed Description

Cardiogenetics is essential in daily clinical practice, providing critical insights into the genetic basis of inherited cardiovascular conditions. This knowledge enables more accurate diagnoses, risk assessments, and personalized management strategies for patients. By understanding the genetic underpinnings of arrhythmias and other heart diseases, healthcare providers can identify at-risk individuals and their family members, facilitating early intervention and preventive measures. Establishing an observational registry for these conditions is vital, as it systematically collects data on patient demographics, clinical presentations, genetic findings, and treatment outcomes. This comprehensive database enhances our understanding of the natural history and variability of genetic cardiovascular disorders while supporting research efforts aimed at developing improved diagnostic tools and therapeutic approaches. Ultimately, such a registry can enhance patient care by informing clinical guidelines and fostering collaboration among clinicians, geneticists, and researchers in the field.

Therefore, the goal of this observational study is to gather extensive clinical, genetic, and electrophysiological data from individuals with suspected or confirmed arrhythmogenic conditions. By systematically documenting patient demographics, family history, clinical presentations, diagnostic findings, and treatment outcomes, the registry aims to deepen our understanding of the genetic basis and clinical implications of genetically driven arrhythmias and systemic syndromes.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients evaluated at the Cardiogenetic Center of the University of Ferrara in Ferrara, Italy.
  • •Having a proven cardiogenetic disease

Exclusion Criteria

  • •Refuse to provide informed consents
  • •Patients not having a cardiogenic disease

Outcomes

Primary Outcomes

All-cause of death

Time Frame: At one and 5 years (end of the study)

The investigators will monitor patient's all causes death

Cardiovascular-related death

Time Frame: At one and 5 years (end of the study)

The investigators will monitor patient's all causes death

Secondary Outcomes

  • Onset/worsening of atrial tachyarrhythmias(At one and 5 years (end of the study))
  • Onset or worsening heart faillure(At one and 5 years (end of the study))
  • Onset/worsening of ventricular tachyarrhythmias(At one and 5 years (end of the study))
  • Need for PM/ICD(At one and 5 years (end of the study))
  • Types of genetic mutations(At the time of genetic analysis)

Investigators

Sponsor
University Hospital of Ferrara
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials